Cite
HARVARD Citation
Dupoiron, D. et al. (2017). Long‐term efficacy and safety of oxycodone‐naloxone prolonged‐release formulation (up to 180/90 mg daily) – results of the open‐label extension phase of a phase III multicenter, multiple‐dose, randomized, controlled study. European journal of pain. pp. 1485-1494. [Online].